Literature DB >> 8996534

Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.

R C Rietbroek1, P J van de Vaart, J Haveman, F A Blommaert, A Geerdink, P J Bakker, C H Veenhof.   

Abstract

The cytotoxicity of cisplatin and cisplatin-DNA adduct formation in vitro and in vivo is clearly enhanced by hyperthermia. We investigated whether cytotoxicity and platinum-DNA adduct formation of two promising new third-generation platinum derivatives, lobaplatin [1,2-diamminomethylcyclobutane platinum(II) lactate] and oxaliplatin [oxalato-1,2-diaminocyclohexane platinum(II)], are also enhanced by hyperthermia. Cisplatin was used for comparison. SW 1573 cells were incubated with cisplatin, lobaplatin or oxaliplatin at different concentrations for 1 h at 37 degrees, 41 degrees and 43 degrees C. The reproductive capacity of cells was determined by cloning experiments. Immunocytochemical detection of platinum-DNA adducts was performed with the rabbit antiserum NKI-A59. At 37 degrees C, cisplatin was the most cytotoxic, followed by oxaliplatin and lobaplatin. Hyperthermia clearly enhanced the cytotoxicity of cisplatin, lobaplatin and oxaliplatin. There was no further increase in cytotoxicity at 43 degrees C compared to 41 degrees C for cisplatin and oxaliplatin. A further increase in cytotoxicity at 43 degrees C was observed for lobaplatin. At 43 degrees C thermal enhancement was higher for lobaplatin than for oxaliplatin, with the reverse pattern at 41 degrees C. For both drugs, thermal enhancement of cytotoxicity was lower than observed for cisplatin. Immunocytochemical detection of platinum-DNA adducts was feasible for all the drugs. Adduct formation was enhanced at 43 degrees C for cisplatin, lobaplatin and oxaliplatin with a relative increase of 410%, 170% and 180%. These results seem to confirm that an increase in platinum-DNA adduct formation is involved in the in vitro thermal enhancement of cytotoxicity. The observed thermal enhancement of cytotoxicity of lobaplatin and oxaliplatin in vitro warrants further in vivo investigations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8996534     DOI: 10.1007/bf01212608

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  35 in total

1.  Interactions of hyperthermia and drugs: treatments and probes.

Authors:  G M Hahn; G C Li
Journal:  Natl Cancer Inst Monogr       Date:  1982-06

2.  Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.

Authors:  G Mathé; Y Kidani; M Segiguchi; M Eriguchi; G Fredj; G Peytavin; J L Misset; S Brienza; F de Vassals; E Chenu
Journal:  Biomed Pharmacother       Date:  1989       Impact factor: 6.529

3.  Enhanced therapeutic efficacy of cisplatin by combination with diethyldithiocarbamate and hyperthermia in a mouse model.

Authors:  M S Murthy; L N Rao; J D Khandekar; E F Scanlon
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

4.  Immunocytochemical localization of DNA adducts induced by a single dose of N-nitroso-N-methylbenzylamine in target and non-target tissues of tumor formation in the rat.

Authors:  J Van Benthem; C P Wild; E Vermeulen; L Den Engelse; E Scherer
Journal:  Carcinogenesis       Date:  1991-10       Impact factor: 4.944

Review 5.  New cisplatin analogues in development. A review.

Authors:  Raymond B Weiss; Michaele C Christian
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

6.  Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.

Authors:  H I Robins; J D Cohen; C L Schmitt; K D Tutsch; C Feierabend; R Z Arzoomanian; D Alberti; F d'Oleire; W Longo; C Heiss
Journal:  J Clin Oncol       Date:  1993-09       Impact factor: 44.544

7.  The synergistic effect of hyperthermia and chemotherapy on murine transitional cell carcinoma.

Authors:  G P Haas; R C Klugo; F W Hetzel; E E Barton; J C Cerny
Journal:  J Urol       Date:  1984-10       Impact factor: 7.450

8.  Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.

Authors:  P M Terheggen; B G Floot; E L Lempers; O van Tellingen; A C Begg; L den Engelse
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology.

Authors:  J Overgaard; D Gonzalez Gonzalez; M C Hulshof; G Arcangeli; O Dahl; O Mella; S M Bentzen
Journal:  Lancet       Date:  1995-03-04       Impact factor: 79.321

10.  The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove.

Authors:  J A Rice; D M Crothers; A L Pinto; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

View more
  18 in total

1.  Thermotherapy enhances oxaliplatin-induced cytotoxicity in human colon carcinoma cells.

Authors:  Xiang-Liang Zhang; An-Bin Hu; Shu-Zhong Cui; Hong-Bo Wei
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

Review 2.  Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure.

Authors:  Loek A W de Jong; Fortuné M K Elekonawo; Philip R de Reuver; Andre J A Bremers; Johannes H W de Wilt; Frank G A Jansman; Rob Ter Heine; Nielka P van Erp
Journal:  Br J Clin Pharmacol       Date:  2018-10-25       Impact factor: 4.335

3.  Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer.

Authors:  Claudio Zanon; Massimiliano Bortolini; Isabella Chiappino; Paolo Simone; Francesco Bruno; Piero Gaglia; Mario Airoldi; Leonorda Deriu; Alon Mashiah
Journal:  World J Surg       Date:  2006-11       Impact factor: 3.352

4.  Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors.

Authors:  Marco A Alcala; Kyungsoo Park; Jinsang Yoo; Dae-Hee Lee; Bae-Hang Park; Byeong-Chel Lee; David L Bartlett; Yong J Lee
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

5.  Alteration of Drug Sensitivity in Human Colon Cancer Cells after Exposure to Heat: Implications for Liver Metastasis Therapy using RFA and Chemotherapy.

Authors:  Ryouji Makizumi; Weng-Lang Yang; Randall P Owen; Rohit R Sharma; T S Ravikumar
Journal:  Int J Clin Exp Med       Date:  2008-02-28

6.  Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer.

Authors:  Claudio Zanon; Renzo Clara; Isabella Chiappino; Massimiliano Bortolini; Silvia Cornaglia; Paolo Simone; Francesco Bruno; Leonarda De Riu; Mario Airoldi; Fulvia Pedani
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

7.  Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.

Authors:  Robert T Ripley; Jeremy L Davis; Clinton D Kemp; Seth M Steinberg; Mary Ann Toomey; Itzhak Avital
Journal:  Trials       Date:  2010-05-25       Impact factor: 2.279

8.  Is Platinum Present in Blood and Urine from Treatment Givers during Hyperthermic Intraperitoneal Chemotherapy?

Authors:  Sara Näslund Andréasson; Helena Anundi; Sig-Britt Thorén; Hans Ehrsson; Haile Mahteme
Journal:  J Oncol       Date:  2010-07-01       Impact factor: 4.375

9.  Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.

Authors:  Lucas Sideris; Andrew Mitchell; Pierre Drolet; Guy Leblanc; Yves E Leclerc; Pierre Dubé
Journal:  Can J Surg       Date:  2009-04       Impact factor: 2.089

10.  Preliminary Experience and Morbidity Analysis of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) from a Tertiary Cancer Center in India.

Authors:  Naveen Padmanabhan; Barath Raj Kumar; Ansar Pullampara Pookunju; Ayyapan Srinivasan; Vikash Mahajan
Journal:  J Clin Diagn Res       Date:  2015-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.